GE Healthcare has achieved a significant milestone by securing approval from the Food and Drug Administration (FDA) for Flyrcado (flurpiridaz F 18), a new imaging agent designed for positron emission tomography (PET) scans, which are utilized in the detection of coronary artery disease. This cutting-edge agent boasts a notably longer half-life compared to existing tracers used in PET myocardial perfusion imaging (MPI), enhancing both the convenience and efficacy of the diagnostic process.
The introduction of Flyrcado represents a noteworthy advancement in the field of nuclear cardiology. According to Professor Jamshid Maddahi from the University of California Los Angeles School of Medicine, who served as the principal investigator for the Flyrcado clinical trials, this new radiotracer is set to transform the diagnosis of coronary artery disease, which is the world’s leading cause of death. The agent’s extended half-life of 109 minutes not only improves diagnostic accuracy but also simplifies logistical operations by allowing the tracer to be manufactured and distributed from offsite pharmacies as a ready-to-use unit dose. This capability eliminates the need for onsite tracer production and generator maintenance, thereby broadening the potential reach of this technology to a larger number of hospitals and imaging centers.
PET MPI is a diagnostic test used to evaluate blood flow through the heart. It has superior diagnostic efficacy compared to the standard MPI method, especially in patients with high body mass index and women—groups traditionally harder to image accurately. The procedure involves using a radioactive drug or tracer that highlights areas of the heart receiving inadequate blood flow.
Currently, PET MPI is underutilized in the U.S., primarily due to limited access to appropriate tracers. Flyrcado’s longer half-life not only addresses this issue by enhancing distribution capabilities but also allows for greater flexibility in the imaging process. Clinics can now integrate exercise stress testing with cardiac PET imaging or even rescan a patient within the same session if required, without the constraints imposed by shorter-lived tracers.
Market analysts, including Stifel’s Rick Wise, anticipate a rapid adoption of Flyrcado among cardiac PET centers across the U.S., driven by its clinical benefits over other MPI radiopharmaceuticals presently in use. The enthusiasm from the medical community indicates that Flyrcado is poised to set a new standard in cardiac imaging.
GE Healthcare has been instrumental in the development and upcoming distribution of Flyrcado, having acquired exclusive global commercialization rights from Lantheus in 2017. The company reveals that initial rollout in the U.S. is expected in early 2025, marking a step forward in improving access to high-quality cardiac care.
Overall, the FDA approval of Flyrcado is a major achievement in the field of cardiac imaging, offering significant improvements in the diagnosis and management of coronary artery disease through advanced PET imaging technology.
#Healthcare #FDA #nod #PET #imaging #agent
